Variation in preoperative antithrombotic strategy, severe bleeding, and use of blood products in coronary artery bypass grafting: results from the multicentre E-CABG registry
Standard
Variation in preoperative antithrombotic strategy, severe bleeding, and use of blood products in coronary artery bypass grafting: results from the multicentre E-CABG registry. / Biancari, Fausto; Mariscalco, Giovanni; Gherli, Riccardo; Reichart, Daniel; Onorati, Francesco; Faggian, Giuseppe; Franzese, Ilaria; Santarpino, Giuseppe; Fischlein, Theodor; Rubino, Antonino S; Maselli, Daniele; Nardella, Saverio; Salsano, Antonio; Nicolini, Francesco; Zanobini, Marco; Saccocci, Matteo; Ruggieri, Vito G; Bounader, Karl; Perrotti, Andrea; Rosato, Stefano; D'Errigo, Paola; D'Andrea, Vito; De Feo, Marisa; Tauriainen, Tuomas; Gatti, Giuseppe; Dalén, Magnus.
in: EUR HEART J-QUAL CAR, Jahrgang 4, Nr. 4, 01.10.2018, S. 246-257.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Variation in preoperative antithrombotic strategy, severe bleeding, and use of blood products in coronary artery bypass grafting: results from the multicentre E-CABG registry
AU - Biancari, Fausto
AU - Mariscalco, Giovanni
AU - Gherli, Riccardo
AU - Reichart, Daniel
AU - Onorati, Francesco
AU - Faggian, Giuseppe
AU - Franzese, Ilaria
AU - Santarpino, Giuseppe
AU - Fischlein, Theodor
AU - Rubino, Antonino S
AU - Maselli, Daniele
AU - Nardella, Saverio
AU - Salsano, Antonio
AU - Nicolini, Francesco
AU - Zanobini, Marco
AU - Saccocci, Matteo
AU - Ruggieri, Vito G
AU - Bounader, Karl
AU - Perrotti, Andrea
AU - Rosato, Stefano
AU - D'Errigo, Paola
AU - D'Andrea, Vito
AU - De Feo, Marisa
AU - Tauriainen, Tuomas
AU - Gatti, Giuseppe
AU - Dalén, Magnus
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Aims: No data exists on inter-institutional differences in terms of adherence to international guidelines regarding the discontinuation of antithrombotics and rates of severe bleeding in coronary artery bypass grafting (CABG).Methods and results: This is an analysis of 7118 patients from the prospective multicentre European CABG (E-CABG) registry who underwent isolated CABG in 15 European centres. Preoperative pause of P2Y12 receptor antagonists shorter than that suggested by the 2017 ESC guidelines (overall 11.6%) ranged from 0.7% to 24.8% between centres (adjusted P < 0.0001) and increased the rate of severe-massive bleeding [E-CABG bleeding grades 2-3, OR 1.66, 95% confidence interval (CI) 1.27-2.17; Universal Definition of Perioperative Bleeding (UDPB) bleeding grades 3-4, OR 1.50, 95% CI 1.16-1.93]. The incidence of resternotomy for bleeding (overall 2.6%) ranged from 0% to 6.9% (adjusted P < 0.0001), and surgical site bleeding (overall 59.6%) ranged from 0% to 84.6% (adjusted P = 0.003). The rate of the UDPB bleeding grades 3-4 (overall 8.4%) ranged from 3.7% to 22.3% (P < 0.0001), and of the E-CABG bleeding grades 2-3 (overall 6.5%) ranged from 0.4% to 16.4% between centres (P < 0.0001). Resternotomy for bleeding (adjusted OR 5.04, 95% CI 2.85-8.92), UDPB bleeding grades 3-4 (adjusted OR 6.61, 95% CI 4.42-9.88), and E-CABG bleeding grades 2-3 (adjusted OR 8.71, 95% CI 5.76-13.15) were associated with an increased risk of hospital/30-day mortality.Conclusions: Adherence to the current guidelines on the early discontinuation of P2Y12 receptor antagonists is of utmost importance to reduce excessive bleeding and early mortality after CABG. Inter-institutional variation should be considered for a correct interpretation of the results in multicentre studies evaluating perioperative bleeding and use of blood products.
AB - Aims: No data exists on inter-institutional differences in terms of adherence to international guidelines regarding the discontinuation of antithrombotics and rates of severe bleeding in coronary artery bypass grafting (CABG).Methods and results: This is an analysis of 7118 patients from the prospective multicentre European CABG (E-CABG) registry who underwent isolated CABG in 15 European centres. Preoperative pause of P2Y12 receptor antagonists shorter than that suggested by the 2017 ESC guidelines (overall 11.6%) ranged from 0.7% to 24.8% between centres (adjusted P < 0.0001) and increased the rate of severe-massive bleeding [E-CABG bleeding grades 2-3, OR 1.66, 95% confidence interval (CI) 1.27-2.17; Universal Definition of Perioperative Bleeding (UDPB) bleeding grades 3-4, OR 1.50, 95% CI 1.16-1.93]. The incidence of resternotomy for bleeding (overall 2.6%) ranged from 0% to 6.9% (adjusted P < 0.0001), and surgical site bleeding (overall 59.6%) ranged from 0% to 84.6% (adjusted P = 0.003). The rate of the UDPB bleeding grades 3-4 (overall 8.4%) ranged from 3.7% to 22.3% (P < 0.0001), and of the E-CABG bleeding grades 2-3 (overall 6.5%) ranged from 0.4% to 16.4% between centres (P < 0.0001). Resternotomy for bleeding (adjusted OR 5.04, 95% CI 2.85-8.92), UDPB bleeding grades 3-4 (adjusted OR 6.61, 95% CI 4.42-9.88), and E-CABG bleeding grades 2-3 (adjusted OR 8.71, 95% CI 5.76-13.15) were associated with an increased risk of hospital/30-day mortality.Conclusions: Adherence to the current guidelines on the early discontinuation of P2Y12 receptor antagonists is of utmost importance to reduce excessive bleeding and early mortality after CABG. Inter-institutional variation should be considered for a correct interpretation of the results in multicentre studies evaluating perioperative bleeding and use of blood products.
KW - Aged
KW - Blood Loss, Surgical/prevention & control
KW - Blood Transfusion/standards
KW - Coronary Artery Bypass
KW - Coronary Artery Disease/surgery
KW - Europe/epidemiology
KW - Female
KW - Fibrinolytic Agents/adverse effects
KW - Humans
KW - Incidence
KW - Male
KW - Practice Guidelines as Topic
KW - Preoperative Care/standards
KW - Prospective Studies
KW - Thrombolytic Therapy/adverse effects
U2 - 10.1093/ehjqcco/qcy027
DO - 10.1093/ehjqcco/qcy027
M3 - SCORING: Journal article
C2 - 29939246
VL - 4
SP - 246
EP - 257
JO - EUR HEART J-QUAL CAR
JF - EUR HEART J-QUAL CAR
SN - 2058-5225
IS - 4
ER -